Individuating Possibly Repurposable Drugs and Drug Targets for COVID-19 Treatment Through Hypothesis-Driven Systems Medicine Using CoVex.
Assay Drug Dev Technol
; 18(8): 348-355, 2020.
Artículo
en Inglés
| MEDLINE | ID: covidwho-915847
ABSTRACT
Coronavirus disease 2019 (COVID-19), caused by the SARS-CoV-2 virus, has developed into a pandemic causing major disruptions and hundreds of thousands of deaths in wide parts of the world. As of July 3, 2020, neither vaccines nor approved drugs for effective treatment are available. In this article, we showcase how to individuate drug targets and potentially repurposable drugs in silico using CoVex a recently presented systems medicine platform for COVID-19 drug repurposing. Starting from initial hypotheses, CoVex leverages network algorithms to individuate host proteins involved in COVID-19 disease mechanisms, as well as existing drugs targeting these potential drug targets. Our analysis reveals GLA, PLAT, and GGCX as potential drug targets, and urokinase, argatroban, dabigatran etexilate, betrixaban, ximelagatran and anisindione as potentially repurposable drugs.
Palabras clave
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Reposicionamiento de Medicamentos
/
Tratamiento Farmacológico de COVID-19
Tópicos:
Vacunas
Límite:
Humanos
Idioma:
Inglés
Revista:
Assay Drug Dev Technol
Asunto de la revista:
Farmacología
Año:
2020
Tipo del documento:
Artículo
País de afiliación:
Adt.2020.1010
Similares
MEDLINE
...
LILACS
LIS